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Abstract
Background: Hepatitis C virus (HCV) infection causes significant morbidity and mortality among people who inject
drugs (PWID) and HIV+ men who have sex with men (MSM). Characterizing spontaneous viral clearance of HCV
infection among PWID and HIV+ MSM is important for assessing the burden of disease and treatment strategies in
these populations.
Methods: Electronic and other searches of medical literature were conducted. Reports were eligible if they presented
original data from upper-middle- and high-income countries on laboratory-confirmed HCV infection and spontaneous
viral clearance among PWID or HIV+ MSM. Pooled estimates of spontaneous viral clearance were generated using
fixed-effect and random-effects models. Meta-regression examined potential predictors related to individual
characteristics and research methodology.
Results: The meta-analysis estimated that spontaneous viral clearance occurs in 24.4 % of PWID and 15.4 % of HIV+ MSM.
In univariate meta-regression among PWID, male sex and age were significantly associated with spontaneous
viral clearance, and in multivariate analysis, male sex and HIV positivity were predictors of spontaneous viral
clearance; among HIV+ MSM no variables were found to affect spontaneous viral clearance.
Conclusion: The variability in estimates of spontaneous viral clearance between HIV+ MSM and PWID suggests the
impact of HIV co-infection and HCV re-infection. Due to limited data on additional factors that may affect the natural
history of HCV, more research is needed to further understand spontaneous viral clearance in these risk groups.
Protocol registration: The protocols for the PWID and HIV+ MSM research were registered with PROSPERO
(CRD42014008805; CRD42013006462).
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Background
Approximately 3 % of the world’s population is infected
with hepatitis C virus (HCV), a blood borne infection
that is almost entirely attributable to parenteral exposure
via non-sterile injection equipment used in medical set-
tings or to inject drugs [1]. After clinical or subclinical
HCV infection up to 25 % of people will spontaneously
clear the virus [2]. There is significant excess mortality
attributable to liver-related injury in those with chronic
HCV infection compared to the general population, and
among those with chronic HCV infection, progression of
the disease varies widely [3, 4].
Among people who inject drugs (PWID), high HCV
incidence rates of 10–40 infections/100 person-years
(PYs) contribute to a persistent and high population
prevalence of 43–80 % [5–7]; as such, HCV is endemic
among PWID [8].
Co-infection with HIV and HCV is common due to
shared routes of disease transmission. HIV/HCV co-in-
fection contributes to substantial, yet preventable, mor-
bidity and mortality; specifically, liver disease
progression is accelerated in HIV co-infected individuals
[9, 10]. Co-infection with HIV and HCV is of consider-
able relevance to PWID as the majority of HIV-positive
PWID also are infected with HCV (50–70 %) [11].
Within the HIV-positive population, sexual transmission
of HCV also is a concern [12, 13]. In a recent meta-
analysis, the incidence rate of HCV infection among HIV-
positive men who have sex with men (HIV+ MSM) who
are non-PWID was found to be 0.53/100 PYs [14]. While
low, incidence of HCV in this population is expected to
increase [14]. In a related meta-analysis, HCV prevalence
was estimated to be 12 % among HIV+ MSM [15].
Characterizing spontaneous viral clearance of HCV in-
fection among PWID and HIV+ MSM is important for
assessing the burden of disease and the need for treat-
ment in these populations. In this systematic review and
meta-analysis, we synthesized the literature on the
prevalence of spontaneous viral clearance within PWID
and HIV+ MSM populations. This systematic review
and meta-analysis and related simulations are conducted
as part of the HCV Synthesis Project, which is funded to
develop guidance and recommendations for HCV con-
trol strategies in the US [14–19].
Methods
Search strategy
Both electronic and manual searches for published lit-
erature were conducted. The databases of CINAHL,
OVID, ProQuest, PubMed, and Web of Science were
searched using the following terms: “HCV,” “hepatitis
C,” “natural history,” “disease progression,” “clearance,”
and “resolution.” For the HIV+ MSM group, the search
string included variations of the terms “HIV,” “human
immunodeficiency virus,” “AIDS,” “acquired immuno-
deficiency syndrome,” “men who have sex with men,”
“homosexual,” and “gay.” Reports examining PWID were
sought through the incorporation of the keywords
“PWID,” “injection drug use,” and “intravenous drug use”.
(See Additional file 1 for complete search strategies.)
Searches were refined using filters for publication date,
peer-reviewed journal, and human studies. Additional
literature was retrieved through manual searches of the
reference lists of eligible reports, review articles, and
methodological papers. The conduct and reporting of this
project was guided by the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA) [20].
The protocols for the HIV+ MSM and PWID research
were registered with PROSPERO (CRD42013006462;
CRD42014008805) and subsequently published [16, 18].
Inclusion and exclusion criteria
PWID
Reports that met the following criteria were eligible for
inclusion in the review: (i) included participants with
laboratory confirmed HCV infection and who reported
current or previous injection drug use (hereafter referred
to as PWID); (ii) presented original data on spontaneous
viral clearance in a study sample comprised of at least
90 % PWID; (iii) published between January 1, 1990, and
April 1, 2014; and, (iv) provided data on participants
from upper-middle- or high-income countries. The con-
dition in (iv) was based on the prevalence of the
hepatitis B virus (HBV) carrier state, which is associated
with lower rates of HCV clearance [21]. Across upper-
middle- and high-income countries, the HBV carrier rate
is less than 2 % whereas areas of high HBV endemicity
are comprised of predominately lower-income countries
such as Southeast Asia, Sub-Saharan Africa, and the
Amazon Basin; HBV carrier rates in these regions are
upwards of 8 % [22] and may be higher among those at
risk of HIV or HCV. Reports were excluded if HIV or
HBV co-infection was present in greater than 50 % of
the PWID study sample, or if participants were receiving
or previously had received HCV treatment. (Seven re-
ports included HIV-positive PWID (range 1.8–57.1 %).)
HIV+ MSM
The following eligibility criteria were applied: (i)
included male participants co-infected with HIV infec-
tion and with laboratory confirmed acute HCV infection
and who reported having sex with other men (hereafter
referred to as MSM); (ii) presented original data on
spontaneous viral clearance in a study sample comprised
of at least 90 % HIV+ MSM; (iii) published between
January 1, 1996, and April 1, 2014; and, (iv) provided
data on participants from upper-middle- or high-income
countries. We established the condition in (iii) to
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account for the introduction in 1996 of highly active
anti-retroviral therapy (HAART), which represented a
significant change in the standard of care, and thus the
natural history, of HIV infection. Accordingly, HAART
may affect the disease progression of individuals co-
infected with HIV and acute HCV. The restriction that
participants had acute HCV allowed for the observation
of the effect of HIV infection on the course of newly ac-
quired HCV infection. The condition in (iv) follows from
the assumption that health outcomes are influenced by
the disparity between income-based country groups
in the accessibility and completeness of coverage of
HAART to HIV-positive individuals; a wide gap ex-
ists between treatment and need in low-income
countries [23].
HCV infection measure
The primary exposure of interest was acute or chronic
HCV infection. The preferred criteria for defining acute
HCV infection employed in our review was that en-
dorsed by the European AIDS Treatment Network
(NEAT) for which the criteria were seroconversion or a
positive HCV RNA test following a documented nega-
tive HCV RNA or negative HCV antibody test in the
previous 12 months [24]. Our alternative criterion for
defining acute HCV infection required a statement in
the report that all patients were acutely infected.
Chronic infection was defined by HCV RNA positivity.
The importance of defining whether or not HCV was
acute was less critical to those without HIV infection;
however, in those with HIV the demonstration of acute
infection (either by the preferred or alternative criteria)
was relevant in asking whether HIV co-infection impacts
spontaneous viral clearance. Among the reports present-
ing data on spontaneous viral clearance among HIV+
MSM, all participants acquired HIV infection prior to
HCV infection; among PWID the sequence of disease
acquisition was less clear.
Outcome measures
The outcome of interest was the prevalence of spontan-
eous viral clearance. Spontaneous viral clearance was
measured in cross-sectional studies as at least one nega-
tive or undetectable RNA test result and in longitudinal
studies as consecutive negative or undetectable RNA test
results. In some reports the definition of spontaneous
viral clearance was not presented, but data were avail-
able on the outcome of interest.
Screening and data collection
Two research assistants (RAs) screened abstracts and
extracted data. The project director and the principal in-
vestigator reviewed all eligible reports and made final
decisions on inclusion in the review and meta-analysis.
We collected from the included reports data on the fol-
lowing domains: citation information; study cohort,
period, and location; study design and methods; inci-
dence and prevalence of spontaneous viral clearance;
disease duration; and participant characteristics, particu-
larly factors understood to be associated with clearance
(e.g., age, sex, and HIV co-infection). For any report with
missing or inconsistent data, we contacted the corre-
sponding author for additional information or clarifica-
tion. Among the set of reports examining PWID, six
authors were contacted, and four fulfilled our data re-
quests (67 %). Three of six authors provided additional
data on HIV+ MSM (50 %).
Report quality
Quality appraisal of each report included in this system-
atic review was based on an adapted version of the Qual-
ity In Prognosis Studies (QUIPS) tool, which was
developed to assess potential biases in studies of prog-
nostic factors [25, 26]. (The complete adapted instru-
ment is available by request.) Each report was assigned
an overall rating of high, moderate, or low, which indi-
cated the extent to which the study design and analysis
controlled for the influence of selection bias, misclassifi-
cation, and confounding.
Data analysis
Report-level prevalence of spontaneous viral clearance
was estimated using the binomial distribution. Pooled
estimates of spontaneous viral clearance were generated
using both fixed-effect and random-effects models. The
Cochran’s Q and I2 [27] measures provided assessments
of heterogeneity, and random-effects meta-regression
was performed to examine variability among the report-
level estimates of spontaneous viral clearance.
We examined the possibility of assessing the role of
previous infection with HIV on spontaneous viral clear-
ance among PWID; however, because most studies did
not specify which of HIV or HCV was acquired first, we
were not able to directly examine this. Those PWID
who were HIV positive and had unequivocal evidence of
spontaneous viral clearance most likely represented an
individual in whom the sequence of events was HCV in-
fection, followed by spontaneous viral clearance, and
subsequently HIV infection. All statistical analysis was




A total of 7,488 reports were retrieved from the litera-
ture searches, and 28 were included in the final review
(see Fig. 1). The reports are described in Table 1. The
majority of reports described studies located in Europe
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(12; 43 %); the remaining samples were from the United
States (7; 25 %), Australia (5; 18 %), China (2; 7 %),
Canada (1; 4 %), and Iran (1; 4 %). Data on participant
attributes were presented in greater than 50 % of all
reports. Sixteen reports (57 %) presented age at enroll-
ment, eighteen (64 %) provided the sex distribution, and
sixteen (57 %) stated the proportion of HIV-positive
individuals.
All 28 reports were included in the meta-analysis.
Among 5,569 PWID, whose mean age at enrollment was
29.6 years (median 27.4; 15 reports), spontaneous viral
clearance was observed in 1,236 participants. The
random-effects meta-analysis estimate of the prevalence
of spontaneous viral clearance was 24.3 % (95 % CI 19.5,
29.1; Q = 638.51, p < 0.001; I2 = 95.8 %). The estimate
from each study is presented in the forest plot in Fig. 2.
Pooled subgroup estimates also were generated to ac-
count for HIV status and quality rating. Within the sets
of reports for which there were data on the HIV status
of PWID, spontaneous viral clearance occurred in
25.7 % (95 % CI 16.4, 35.0; 13 reports) of HIV-negative
participants and in 16.1 % (95 % CI 12.5, 19.6; 3 reports)
of HIV-positive participants. In stratifying the reports
by quality rating, as depicted in Table 3, the preva-
lence of spontaneous viral clearance was 27.6, 24.1,
and 15.4 % among high-, moderate-, and low-quality
reports, respectively.
HIV+ MSM
Following from Fig. 3, the literature searches yielded
2,417 reports, of which 10 were included in the present
analysis; these reports are detailed in Table 2. Seven of
the reports (70 %) were on studies with cohorts drawn
only from Europe. One report (10 %) examined a sample
from the United States, and another report (10 %)
assessed samples from North America, Australia, and
Europe. The study location was not described in one
report. Few participant characteristics were summarized
consistently across the reports. Age at enrollment was
presented in five reports (50 %), proportion on HAART
in three reports (30 %), and duration of HIV infection in
one report (10 %).
Only 9 of the 10 reports were included in the meta-
analysis. One report provided a count of zero spontan-
eous clearance events in the sample. We chose the
conservative approach to handling the zero-count issue,
which was to exclude the report from the pooled
analysis.
In aggregate, there were 588 HIV+ MSM with a mean
age of 40.0 years (median 40.7; 4 reports); 96
7488 reports retrieved from 
electronic search (Ovid, ProQuest, 
PubMed, and Web of Science)
5903 reports screened 
after duplicates removed
113 reports retrieved 
from references
5560 reports excluded
343 full-text reports 
assessed for eligibility
28 reports included 
in meta-analysis
1698 duplicate reports removed
315 full-text reports excluded1:                      N
No data on clearance (262) 
Data incomplete for coding       (31)
Fewer than 10 PWID included (11)
HIV or HBV co-infection (4)
The data overlap with a previous study   (4)  
Subjects received treatment (3)
Fig. 1 Flow diagram of the literature search and eligibility assessment for PWID. 1Reasons for exclusion are not mutually exclusive. A report may
have been ineligible due to multiple reasons. Here, only one reason for exclusion is provided
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Table 1 Studies investigating spontaneous viral clearance of HCV among PWID
First author (pub. yr.) Study period Location N
Recruitment method Recruitment site Definition of
HCV clearance
Quality rating Participants Clearers Proportion of
clearance events
95 % CI
Aberle (2006) [34] 2003–2005 Austria Convenience sampling Clinical setting Methods not
reported
Low 11 3 27.3 1.0 - 53.6
Aitken (2008) [35] 2005–2008 Australia Convenience sampling Community-based
setting
1 RNA- result Moderate 135 41 30.4 22.6 - 38.1
Alanko Blome
(2014) [36]
1997–2005 Sweden Consecutive sampling Other setting 1 RNA- result High 150 48 32.0 24.5 - 39.5




High 113 38 33.6 24.9 - 42.3
Cournot (2004) [38] 1999–2004 France Consecutive sampling Clinical setting 1 RNA- result Moderate 178 27 15.2 9.9 - 20.4




Moderate 215 29 13.5 8.9 - 18.1
Dolan (2010) [40] 2005–2007 Australia Convenience sampling Correctional setting 1 RNA- result Moderate 16 6 37.5 13.8 - 61.2
Garten (2008) [41] 1999–2008 China Unspecified sampling Clinical setting 1 RNA- result Low 347 30 8.6 5.7 - 11.6
Gerlach (2003) [42] 1993–2003 Germany Consecutive sampling Clinical setting ≥1 RNA- result
over 6 months
High 15 5 33.3 9.5 - 57.2
Gjeruldsen (2003) [43] 1997–1999 Norway Consecutive sampling Clinical setting 1 RNA- result Moderate 50 8 16.0 5.8 - 26.2
Grebely (2007) [44] 1992–2005 Canada Convenience sampling Community-based
setting
≥1 RNA- result High 431 91 21.1 17.3 - 25.0
Hallinan (2007) [45] 2002–2005 Australia Consecutive sampling Drug treatment
setting
1 RNA- result Moderate 145 43 29.7 22.2 - 37.1
Hsieh (2014) [46] 2008–2010 China Unspecified sampling Correctional setting Methods not
reported
Low 513 99 19.3 15.9 - 22.7
Jauncey (2004) [47] 1992–2002 Australia Consecutive sampling Clinical setting ≥2 consecutive
RNA- results
High 57 24 42.1 29.3 - 54.9




at least 12 months
High 496 191 38.5 34.2 - 42.8
Kielland (2013) [49] 1970–2008 Norway Consecutive sampling Drug treatment
setting
1 RNA- result Moderate 523 195 37.3 33.1 - 41.4
Lidman (2009) [50] 2004–2006 Sweden Consecutive sampling Clinical setting 1 RNA- result Moderate 268 61 22.8 17.7 - 27.8
Mattsson (1993) [51] 1991–1993 Sweden Consecutive sampling Population-based
setting
1 RNA- result Moderate 12 4 33.3 6.7 - 60.0
Meyer (2007) [52] 2002–2007 Germany Consecutive sampling Correctional setting ≥1 RNA- result Moderate 90 23 25.6 16.5 - 34.6




















Table 1 Studies investigating spontaneous viral clearance of HCV among PWID (Continued)
Ostapowicz
(1999) [54]
1990–1999 Australia Unspecified sampling Clinical setting 1 RNA- result Moderate 142 2 1.4 −0.5 - 3.3
Page (2013) [55] 2000–2011 United States Convenience sampling Unspecified ≥2 RNA- results High 109 26 23.9 15.9 - 31.9
Poustchi (2011) [56] 2004–2008 Iran Other systematic Clinical and
research setting
1 RNA- result after
6 months
Moderate 28 4 14.3 1.3 - 27.2
Santantonio
(2006) [57]
1999–2004 Italy Unspecified sampling Clinical setting ≥1 RNA- result w/in
6 months and≥ 1
RNA- result for
additional 6 months
Moderate 71 31 43.7 32.1 - 55.2
Shah (2012) [58] 2004–2007 United States Convenience sampling Community-based
setting
1 RNA- result Moderate 272 43 15.8 11.5 - 20.1




at least 5 months
High 919 90 9.8 7.9 - 11.7
van den Berg
(2011) [60]




at least 4 months
Moderate 106 35 33.0 24.1 - 42.0




High 44 8 18.2 6.8 - 29.6
Fixed-effect meta-analysis estimate of the prevalence of spontaneous viral clearance (28 studies): 15.1 % (95 % CI 14.2, 16.0)
Random-effects meta-analysis estimate of the prevalence of spontaneous viral clearance (28 studies): 24.3 % (95 % CI 19.5, 29.1)














participants experienced spontaneous viral clearance.
The random-effects meta-analysis estimate of the preva-
lence of spontaneous viral clearance was 15.4 % (95 %
CI 11.5, 19.3; Q = 13.29, p = 0.102; I2 = 39.8 %). The for-
est plot in Fig. 4 provides the estimates from the
contributing reports. Subgroup estimates based on
quality rating also were obtained. As shown in Table 3,
among high-, moderate-, and low-quality reports, preva-
lence of spontaneous viral clearance was 19.2, 15.8, and
11.3 %, respectively.
Meta-regression
To examine the effect of report and participant charac-
teristics on the prevalence of spontaneous viral clear-
ance, we conducted random-effects meta-regression.
Because covariates hypothesized to contribute to spon-
taneous viral clearance were not consistently collected
or reported across reports, our meta-regression was
limited to a small set of factors. Both univariate and
multivariate meta-regression were performed.
PWID
Only two variables were significant in univariate analysis:
male sex and age (p < 0.05). Spontaneous viral clearance
was lower in both males and older individuals. We
examined the relationship among pairs of variables
(specifically, male sex, HIV-positivity, and age) through
contingency tables. Fisher’s exact tests revealed no
significant associations between factor dyads (results not
shown; see Additional file 2). Of particular interest to
our study was the impact of HIV. In our preferred
multivariate model, presented in Table 4, male sex
(p < 0.021) and HIV positivity (p < 0.036) were signifi-
cant predictors.
HIV+ MSM
Neither univariate nor multivariate analysis provided any
evidence of an effect on spontaneous viral clearance of
any of the variables (i.e., age, proportion on highly active
antiretroviral therapy, recruitment site, and quality
rating) evaluated.
Discussion
In this systematic review and meta-analysis, we esti-
mated that the prevalence of spontaneous viral clearance
is 24.4 % in PWID and 15.4 % in HIV+ MSM. Although
the estimates for PWID and HIV+ MSM were not
directly compared here, the difference may be related to
Fig. 2 Forest plot of the estimated prevalence and 95 % CI of HCV clearance among PWID for each study
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the impact of HIV co-infection on the natural history of
HCV. The rates of spontaneous viral clearance were
similar in HIV+ MSM (15.4 %) and PWID with HIV in-
fection at the time that HCV clearance was evaluated
(16.1 %). Our estimate of 24.4 % among PWID was very
closely similar to the estimate from a pooled analysis of
clearance among 632 participants in multiple studies
(25 %) who were observed following acute infection [29].
Among HIV-positive PWID, lower clearance cannot
reliably be attributed to the effect of HIV infection on
viral kinetics because the temporal relation between HIV
and HCV infections in these individuals is unclear.
Moreover, estimates of spontaneous viral clearance from
most studies do not necessarily represent true rates but
rather the prevalence of cleared infection. Evidence of
clearance at any given time in an individual is the cumu-
lative result of behaviors that led to infection events,
including multiple re-infections, and the host and viral
characteristics that govern response to acute HCV infec-
tion. Although re-infection post-SVR is higher among
HIV +MSM than among PWID, it cannot be concluded
that the rates of HCV re-infection in treated and
untreated HIV +MSM are higher than among treated
and untreated PWID because studies of re-infection in
treated PWID have in many cases excluded active
injectors [14, 30]. There is no research comparing the
frequency of HCV transmission behavior between these
groups, and thus, there is insufficient evidence to
attribute differences in clearance to differences in behav-
ioral risk.
Our finding that female gender was associated with
higher proportions of spontaneous viral clearance events
is consistent with published literature demonstrating
that females are more likely to clear HCV than their
male counterparts in a variety of settings and other
patient groups [31, 32].
Evaluation of the report-level spontaneous viral clear-
ance data for each of the populations indicates that the
meta-analysis estimates were affected by notable degrees
of heterogeneity. Among PWID, both male sex and age
were associated with lower proportions of spontaneous
viral clearance events. In examining spontaneous viral
clearance estimates in HIV+ MSM, the results did not
suggest the effect of any of the factors considered. Given
the null findings in univariate meta-regression on quality
rating (p = 0.163) and study design (p = 0.182), and not-
ing the low volume of reports for which we extracted
data on participant characteristics, heterogeneity was
most likely due to unmeasured clinical, patient-level
characteristics (e.g., ethnicity, genotype, other viral
2417 reports retrieved from 
electronic search (CINAHL, Ovid, 
ProQuest, PubMed, and Web of Science)
2215 reports screened 
after duplicates removed
77 reports retrieved 
from references
2037 reports excluded
178 full-text reports 
assessed for eligibility
10 reports included 
in meta-analysis
279 duplicate reports removed
168 full-text reports excluded1:                      N
No data on clearance (146) 
Data incomplete for coding       (10)
Fewer than 10 HIV+ MSM included  (8)
The data overlap with a previous study (4) 
Fig. 3 Flow diagram of the literature search and eligibility assessment for HIV+ MSM. 1Reasons for exclusion are not mutually exclusive. A report
may have been ineligible due to multiple reasons. Here, only one reason for exclusion is provided
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Table 2 Studies investigating spontaneous viral clearance of HCV among HIV+ MSM
First author (pub. yr.) Study period Location N
Recruitment method Recruitment site Definition of HCV clearance Quality rating Participants Clearers Proportion of
clearance events
95 % CI
Bottieau (2010) [62] 2001–2009 Belgium Consecutive
sampling
Clinical setting ≥1 RNA- within
6 months
Moderate 65 7 10.8 3.2 - 18.3
Dietz (2012) [63] Not reported Germany Not reported Not reported Methods not reported Low 47 4 8.5 0.5 - 16.5
Fierer(2014) [64] Not reported United States Not reported Not reported ≥1 RNA- within
3 months
Moderate 41 5 12.2 2.2 - 22.2
Fletcher (2003) [65] 2002–2003 United Kingdom Not reported Clinical setting ≥1 RNA- result Moderate 16 6 37.5 13.8 - 61.2
Gilleece (2005) [66] 1997–2003 United Kingdom Not reported Clinical setting >1 RNA- result within
3 months
Moderate 50 12 24.0 12.2 - 35.8




results separated by at
least 1 month
Moderate 11 0 — —
Martin (2013) [67] 2004–2014 United Kingdom Consecutive
sampling
Clinical setting 2 RNA- results after
6 months
High 145 31 21.4 14.7 - 28.1
Piroth (2010) [68] 2008–2009 France Consecutive
sampling
Clinical setting ≥1 RNA- High 53 8 15.1 5.5 - 24.7
Sasadeusz (2011) [69] 2003–2007 Not reported Consecutive
sampling
Clinical setting 2 consecutive RNA-
results separated by at
least 3 months
Low 61 9 14.8 5.9 - 23.7
Thomson (2011) [70] 2005–2009 United Kingdom Not reported Clinical setting 2 consecutive RNA-
results separated by at
least 3 months
Moderate 99 14 14.1 7.3 - 21.0
Fixed-effect meta-analysis estimate of the prevalence of spontaneous viral clearance (9 studies): 15.2 % (95 % CI 12.3, 18.1)
Random-effects meta-analysis estimate of the prevalence of spontaneous viral clearance (9 studies): 15.4 % (95 % CI 11.5, 19.3)














infections) rather than methodological characteristics.
However, our analysis of sources of heterogeneity was
limited by the dearth of information about time to event,
viral factors, and other participant attributes.
Limitations
There are limitations to the meta-analysis that should be
considered. One critical point is that the results of this
review suggest, but do not explain, the mechanisms that
lead to spontaneous viral clearance. Another important
consideration is that the study methods and data
provided by some of the contributing reports to this
review presented challenges to the characterization of
clearance in PWID and HIV+ MSM. We discuss here
the main issues related to the contributing reports.
First, the samples of PWID examined in the included
reports were not composed solely of individuals with a
single HCV infection event, and, therefore, the estimates
likely represented clearance in relation to cumulative
HCV exposures via ongoing injection risk behavior [33].
Indeed, among PWID, rates of re-infection following
spontaneous viral clearance are as high as 47 cases per
100 person-years [2]. Additionally, low rates of clearance
observed among HIV+ PWID may represent frequent
risk behavior that led to HIV infection and HCV re--
infection. The high heterogeneity in the clearance
estimates for both PWID and HIV+ MSM may in fact
represent variability in the number of HCV infection
events, in addition to genetic and other factors.
Second, the cross-sectional study design of most of the
reports also limits interpreting the estimates vis-à-vis the
underlying process.
Third, and related to the previous point, the defin-
ition of spontaneous viral clearance also was not
uniform across studies. In particular, the criteria for
spontaneous viral clearance events were notably
different between cross-sectional and longitudinal
reports.
Fig. 4 Forest plot of the estimated prevalence and 95 % CI of HCV clearance among HIV+ MSM for each study
Table 3 Prevalence of spontaneous viral clearance among
PWID and HIV+ MSM stratified by quality rating
PWID HIV+ MSM
Quality rating Estimate No. of reports Estimate No. of reports
High 27.6 9 19.2 2
Moderate 24.1 16 15.8 5
Low 15.4 3 11.3 2
Table 4 Random-effects meta-regression results for spontan-
eous viral clearance among PWID
Factor β SE p 95 % CI
HIV-positive (%) −0.253 0.105 0.036 −0.487 - −0.020
Males (%) −0.414 0.151 0.021 −0.750 - −0.078
Constant 59.638 11.252 0.000 34.567 - 84.710
No. of reports 13
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Conclusion
This systematic review and meta-analysis suggests that
the prevalence of spontaneous viral clearance is higher
among PWID compared to HIV+ MSM. Our findings
also showed that, among PWID, male sex and HIV co--
infection are negatively correlated with clearance. The
data we presented are useful for modeling future mor-
bidity, mortality, and costs related to HCV infection. Im-
proved research methodology and examination of
individual characteristics in future studies would help to
determine the natural course of HCV among the high--
risk populations of PWID and HIV+ MSM, and appro-
priate allocation of resources for HCV treatment.
Additional files
Additional file 1: Search strategies by risk group. Provides the search
strings used to locate literature across the electronic databases for both
the PWID and HIV+ MSM risk groups. (PDF 6 kb)
Additional file 2: Fisher’s exact tests for variables associated with
spontaneous viral clearance among PWID. Provides the results of Fisher’s
exact tests for variables associated with spontaneous viral clearance
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